RxDoctor Payments Data

Chantel Murrah, DPM

Podiatrist · Ogden, UTNPI 1093791311

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $218, 2.2 times the $100 reported in 2021. That places this record below the midpoint for podiatrist clinicians in UT, where the typical reported total is $963.

$577in general payments, 2019–2025

Across 30 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$113
  • Solventum Corporation$59
  • Mimedx Group, Inc.$55
  • Orthofix Medical, Inc.$50
  • KCI USA, Inc.$48
  • Nevro Corp.$36
  • plus $217 from 12 others

What the payments were for

  • Food & beverage$577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$577 in reported general payments places this provider in the 35th percentile of 59 podiatrist providers in Utah.

See all podiatrist providers in Utah

Medicare billing

Part B allowed, 2024
$157,522
Medicare patients
180
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Silver Sulfadiazine12$69

Paid to pharmacies, not to this prescriber.

Other podiatrist in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →